Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial.
Saved in:
| Title: | Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial. |
|---|---|
| Authors: | Ostendorf L; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.; Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Division of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Zernicke J; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Klotsche J; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany., Kempkens R; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany., Beenken AE; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Biesen R; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Cheng Q; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Khodadadi L; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Guerra GM; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany., Heinrich F; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany., Durek P; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany., Burmester GR; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Krönke G; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Hiepe F; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Mashreghi MF; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany.; German Center for Child and Adolescent Health (DZKJ), Berlin, Germany., Alexander T; German Rheumatology Research Centre (DRFZ), an Institute of the Leibniz Association, Berlin, Germany. tobias.alexander@charite.de.; Department of Rheumatology and Medical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. tobias.alexander@charite.de. |
| Source: | Nature communications [Nat Commun] 2026 Feb 03; Vol. 17 (1), pp. 1312. Date of Electronic Publication: 2026 Feb 03. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-026-69112-w |
